Literature DB >> 24450776

The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes.

David M Maahs1, H Peter Chase, Emily Westfall, Robert Slover, Suiying Huang, John J Shin, Francine R Kaufman, Laura Pyle, Janet K Snell-Bergeon.   

Abstract

OBJECTIVE: This study determined the association of continuous glucose monitoring glucose (CGM-glucose) levels at different times of the day with improvement in glycated hemoglobin (HbA1c) levels. The potential application of these data is to focus effort to improve glucose control in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: Data were analyzed from 196 patients with type 1 diabetes who were randomized to receive sensor-augmented pump therapy in the 1-year STAR 3 trial. CGM-glucose values and HbA1c levels from baseline and after 1 year were evaluated to determine associations of improvement in CGM-glucose at different times of the day with longitudinal improvement in HbA1c.
RESULTS: Improvement in HbA1c levels after 1 year was related to improvement in mean CGM-glucose levels in daytime (6 a.m.-midnight), overnight (midnight-6 a.m.), and each mealtime period (P<0.0001 for each). In multivariable analysis, only improvement in breakfast meal period was associated with improvement in HbA1c after 1 year, explaining 59% of the HbA1c improvement using the partial R(2) test. Moreover, among those patients who only improved CGM-glucose in the overnight period there was an associated improvement in breakfast meal period CGM-glucose of 26 ± 22 mg/dL (P<0.01).
CONCLUSIONS: Breakfast period glucose improvement had the greatest effect on lowering HbA1c levels in patients with type 1 diabetes. Improving glucose control overnight resulted in subsequent improvement in the breakfast period. Although glucose control should be improved at all times, methods to improve overnight and post-breakfast glucose levels may be of primary importance in improving glucose control in patients with type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24450776     DOI: 10.1089/dia.2013.0227

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  3 in total

1.  Continuous glucose monitoring in 2014.

Authors:  Bruce W Bode; Tadej Battelino
Journal:  Diabetes Technol Ther       Date:  2015-02       Impact factor: 6.118

2.  Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset-Applications to the pediatric diabetes population.

Authors:  Gregory P Forlenza; Laura L Pyle; David M Maahs; Timothy C Dunn
Journal:  Pediatr Diabetes       Date:  2016-11-23       Impact factor: 4.866

3.  Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study.

Authors:  Rose A Gubitosi-Klug; Barbara H Braffett; Ionut Bebu; Mary L Johnson; Kaleigh Farrell; David Kenny; Victoria R Trapani; Lynne Meadema-Mayer; Elsayed Z Soliman; Rodica Pop-Busui; John M Lachin; Richard M Bergenstal; William V Tamborlane
Journal:  Diabetes Care       Date:  2022-03-01       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.